Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies

Internal Medicine

Volumn 46, Issue 1, 2007, Pages 3-9

  Toubai, Tomomi ^a   Tanaka, Junji ^a   Ota, Shuichi ^a   Shigematsu, Akio ^a   Shono, Yusuke ^a   Ibata, Makoto ^a   Hashino, Satoshi ^a   Kondo, Takeshi ^a   Kakinoki, Yasutaka ^b   Masauzi, Nobuo ^c   Kasai, Masaharu ^d   Iwasaki, Hiroshi ^e   Kurosawa, Mitsutoshi ^e   Asaka, Masahiro ^a   Imamura, Masahiro ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Asahikawa Kosei Hospital   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d SAPPORO HOKUYU HOSPITAL   (Japan)

^e Sapporo Kosei General Hospital   (Japan)

Author keywords

Empirical antifungal therapy; Febrile neutropenia; Fungal infection; Hematological malignancies; Micafungin

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER DYSFUNCTION; MALE; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PROSPECTIVE STUDY; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; LIPOPROTEINS; LIVER; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33846038663     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6021     Document Type: Article

References (28)

1. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110: 273-284, 2000.
2. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28: 1071-1079, 1999.
3. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute Allergy and Infectious Diseased Mycoses Study Group. N Engl J Med 346: 764-771, 1999.
4. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Lamph/ABLC Collaborative Study Group. Clin Infect Dis 31: 1155-1163, 2000.
5. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 108: 282-289, 2000.
6. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135: 412-422, 2001.
7. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346: 225-234, 2002.
8. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351: 1391-1402, 2004.
9. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 16: 677-688, 1993.
10. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23: 608-615, 1996.
11. British Society for Antimicrobial Chemotherapy Working Party. Laboratory monitoring of antifungal chemotherapy. Lancet 337: 1577-1580, 1991.
12. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347: 408-415, 2002.
13. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopetide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44: 57-62, 2000.
14. Watabe E, Nakai T, Matsumoto S, Ikeda F, Hatano, K. Killing effect of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother 47: 1995-1998, 2003.
15. Choi JH, Brummer E, Stevens DA. Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect 6: 383-389, 2004.
16. Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother 49: 889-891, 2002.
17. Warn PA, Sharp A, Morrissey G, Denning DW. In vitro activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother 50: 1071-1074, 2002.
18. Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 20: 475-481, 2004.
19. de Wet N, Lianos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for treatment of esophageal condidiasis in HIV-positive patients. Clin Infect Dis 39: 842-849, 2004.
20. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 36: 372-378, 2004.
21. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39: 1407-1416, 2004.
22. Yanada M, Kiyoi H, Murata M, et al. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 45: 259-264, 2006.
23. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730-751, 2002.
24. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 46: 1857-1869, 2002.
25. Goodman D, Pamer E, Jakubowski A, et al. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 35: E35-E36, 2002.
26. Matue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 42: 753-757, 2006.
27. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR Jr, Rinaldi MG. In vitro activity of voriconazole against selected fungi. Med Mycol 36: 239-242, 1998.
28. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109-496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 36: 198-202, 1998.